CAPItello-291 Study Group. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. (08-04-2025)
Breast Cancer Brain Metastasis: a Comprehensive Review. (25-02-2025)
Ribociclib plus Endocrine Therapy in Early Breast Cancer. (28-01-2025)
Hormonal Contraception and Breast Cancer Risk for Carriers of Germiline Mutations in BRCA1 and BRCA2. (07-01-2025)
Omission of Radiotherapy after with Breast-Conserving Surgery for Women with Breast Cancer with Low Clinical and Genomic Risk: 5-Year Outcomes of Idea. (10-12-2024)
UGT1A1*28 Polymorhism and the Risk of Toxicity and Disease Progression in Patients with Breast Cancer Receiving Sacituzumab Govitecan. (19-11-2024)
Characteristics and Clinical Outcomes of Breast Cancer in Young BRCA Carriers According to Tumor Histology. (12-11-2024)
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. (15-10-2024)
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. (01-10-2024)
Adjuvant Trastuzumab Emtasine Versus Paclitaxel plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses from Atempt . (23-07-2024)
CAPItello-291 Study Group. Capivasertib in Hormone Recptor-Positive Advanced Breast Cancer. (16-07-2024)
Elacestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy For Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From The Randomized Phase III Emerald Trial . (14-05-2024)
Event-Free Survival by Residual Cancer Burden with Pembrolizumab in Early-Stage Triple Negative Breast Cancer (TNBC): Exploratory Analysis from KEYNOTE-522. (23-04-2024)
PD-L1 Testing in Metastatic Triple-Negative Breast Cancer: Interobserver and Interplatform Reproducibility of CE-IVD Assays for CPS and IC Scores. (19-03-2024)
HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtasine for previously Treated HER2-POISITIVE Metastatic Breast Cancer.(26/02/2024)
NUOVE INDICAZIONI RIMBORSATE DI TRASTUZUMAB DERUXTECAN: G.U. del 20 dicembre 2023
MONARCH 3: Risultati dell’analisi finale della sopravvivenza globale presentati al San Antonio Breast Cancer Symposium (SABCS) il 6 dicembre 2023 (09/01/2024)
STUDIO NATALEE. RIBOCICLIB ADIUVANTE NEL CARCINOMA MAMMARIO (19/12/2023)
STUDIO NATALEEE: ribociclib adiuvante nel carcinoma mammario (12/12/2023)
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. (05/12/2023)
Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US (28/11/2023)
Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US (14/11/2023)
Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US (novembre 2023)
US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer (aprile 2023)
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial (aprile 2023)
Intra-individual comparison of ¹⁸F-sodium fluoride PET–CT and ⁹⁹mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial (febbraio 2023)
MARGITUXIMAB vs TRASTUZUMAB in pazienti con carcinoma mammario HER2-positivo avanzato pretrattato: risultati dello studio randomizzato di fase III SOPHIA (febbraio 2023)
